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Background : In spite of major advances in therapy, morbidity and mortality due to acute decom-
pensated heart failure (ADHF) remains poor. Early initiation of mineralocorticoid antagonist 
(spironolactone) may increase the suppression of  negative effect of renin angiotensin aldosterone 
system (RAAS) activation,even though it already uses ACEI/ARB accompanying ADHF and give 
the better outcome. This study aims todetermine the effect of early spironolactone 100 mg a day for 
3 consecutive days on the suppression of tumorigenicity 2 (ST2) level and clinical changes in 
patients with ADHF. 
Subjects and Method: This was a randomized single blind controlled trial. Thirty eight conse-
cutive patients with ADHF hospitalized at Dr. Moewardi Hospital, Surakarta were randomized into 
two groups: spironolactone group (standard therapy plus spironolactone 100 mg per day for 3 day, 
n=19) and control group (standard therapy, n=19). Clinical sign and simptom of ADHF was 
monitored everyday and the difference of clinical changes was evaluated at the day-3. Venous blood 
samples were collected from all patients at the first day prior therapy and day-4 after therapy. The 
dependent variable was ST2 level. The independent variable was Spironolacton therapy. The data 
were analyzed by independent t-test. 
Results: Decreased levels of ST2 in the spironolactone group (mean= 36.96; SD= 21.29)  was 
higher than the control group (mean= 19.73; SD= 16.48) and it was statistically significant (p= 
0.008). Spironolacton therapy 100 mg once daily at the first 3 day in patient with ADHF was safe, 
no hiperkalemia, or worsening renal function. There was decreasing risk of hipokalemia up to 33% 
(RR= 0.33; 95% CI= 0.1 to 1.0; p= 0.036) and greater proportion patient with improvement clinical 
simptom and sign of ADHF at day-3 in the spironolactone group vs control group. 
Conclusion: Administration of spironolactone 100 mg at the first 3 day plus standard therapy 
decreases levels of ST2, safe, decreases risk of hipokalemia and give greater proportion of clinical 
improvement patients ADHF. 
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BACKGROUND 
Heart failure (HF) is still a major health 
problem in the world (Jessup and Brozena, 
2013). The prevalence of heart failure is 
high, that affects more than 23 million 
people worldwide (Roger et al., 2004). In 
Indonesia, survey from Riset Kesehatan 
Dasar (Riskesdas) in 2013 showed that the 
prevalence of heart failure has been diag-
nosed by doctoris 0.13%, and based on the 
doctor's diagnosis or symptoms is 0.3%. 
Despite major advances in the treatment of 
heart failure, the morbidity and mortality is 
remains high (Burger et al., 2005). The 
absolute mortality rate in heart failure 
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reached 50% within 5 years of diagnosis 
(Levy et al., 2002; Roger et al., 2004). 
The natural history of heart failure is 
characterized by recurrent episodes of acute 
heart failure (Ferreira et al., 2014). Adverse 
neurohormonal activation is an essential 
component in the pathogenesis of ADHF. 
Consequently, blunting this activation  is an 
important therapeutic goal (Burger et al., 
2005). Acute heart failure (AHF) is a state 
of sodium and free water accumulation and 
inappropriate RAAS activation, which is 
further potentiated by decreased clearance 
of aldosterone (Maisel. et al., 2014).In this 
setting, aldosterone elevation contributes to 
cardiorenal dysfunction, increasing the risk 
of death and ventricular arrhythmias 
through a variety mechanism (Ferreiraet 
al., 2014; Albaghdadiet al., 2011). Treat-
ment with Angiotensin Converting Enzyme 
Inhibitor (ACEI) or Angiotensin Receptor 
Blocker (ARB) is insufficient to completely 
suppress aldosterone activity/ aldosterone 
escape (Borghi et al., 1993).Early initiation 
of Mineralocorticoid receptor antagonists 
(MRAs) in addition to ACEI may attenuate 
the negative effects of the RAAS activation 
that accompanies AHF and lead to better 
treatment outcomes (Maisel et al., 2014). 
Mineralocorticoid receptor antagonists 
serve a dual therapeutic role by enhancing 
diuresis and attenuating the pathological 
effects of RAAS and SNS activation. Never-
theless, the potential efficacy and safety of 
MRAs in acute heart failure is still a ques-
tion and has not been well studied (Trullas 
et al., 2014). 
Soluble suppression of tumorigenicity 
2 (sST2), usually called ST2 is a novel bio-
marker for neurohormonal activation in 
heart failure patients (Kakkar et al., 
2008).The role of ST2 in heart failure has 
been known that as an indicator of heart 
muscle damage, treatment monitoring and 
prognosis (Sabatine et al., 2008;Bhardwaj 
et al., 2010).This study isevaluate the 
effects of MRA (spironolactone) on the 
clinical changes of heart failure and 
particularly their effect on the level of ST2. 
 
SUBJECTS AND METHOD 
1. Study Design 
This was a randomized controlled trial. The 
study conducted in Dr. Moewardi hospital, 
Surakarta, Central Java, Indonesia, from 
October to Desember 2015. 
2. Study Sample 
Patients were eligible for enrollment if they 
presented with decompensation of chronic 
heart failure with symptom leading to 
hospitalization.  
Inclusion Criteria: ADHF patients with at 
least 1 symptom (dyspnea, orthopnea or 
edema) and 1 sign of congestion (rales on 
auscultation, pheripheral edema, ascites, 
pulmonary vascular congestion on chest 
radiography); age >18 years old; serum 
creatinine < 2.5 mg/dL; serum potassium 
<5 mg/dL. 
Exclusion Criteria: patient is suffering from 
infection (temperature >37.50 C and or leu-
kocytosis >15,000 accompanied by clinical 
signs of infection) and/or take oral/ intra-
venous antibiotics; the systolic blood 
pressure ≤100 mmHg; patients have co-
morbid pulmonary diseases such as Chro-
nic Obstructive Pulmonary Disease 
(COPD), asthma, pneumonia and lung 
tumors; and history of spironolactone 
intolerance. 
Treatment Assignment 
Patients with ADHF hospitalized at Dr. 
Moewardi hospital Surakarta were ran-
domized into two groups: spironolactone 
group and control group with simple 
random sampling using WinPepi software 
version. 
Trial Intervention 
ADHF patients were divided into 2 groups, 
who received standard therapy plus 
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spironolactone 100 mg per day for 3 days 
(spironolactone group) and the group that 
received standard therapy only (control 
group). Standard ADHF therapy included 
intravenous (i.v.) furosemide (bolus or 
continuous infusion), Angiotensin Convert-
ing Enzyme Inhibitor (ACEI) /Angiotensin 
Receptor Blocker (ARB), nitrates, digoxin 
and/or mechanical ventilations.  
3. Study Variables 
The dependent variable was ST2 level. The 
independent variable was Spironolacton 
therapy. 
4. Study Assessments 
Patient’s clinical signs and symptoms were 
monitored everyday to determine the thera-
peutic effects. Hypotension, breast pain, 
muscle cramps, and other complaints may 
related side effects of spironolactone were 
also evaluated. The difference of clinical 
changes was evaluated at the day-3. Venous 
blood samples were collected from all 
patients at the first day prior therapy and 
day-4 after therapy included ureum, crea-
tinine, electrolytes dan ST2 level. 
5. Biomarker Measurements 
Blood samples for determination of ST2 
were collected at the first day prior therapy 
and day-4 after therapy. After centrifuga-
tion, samples were frozen at −20°C until 
assayed in a blinded fashion in a single 
batch using a monoclonal sandwich ELISA 
(PresageTM ST2, Critical Diagnostics; San 
Diego, CA, USA). The lower detection limit 
of the assay is 2 ng/mL, the upper detection 
limit is 200 ng/mL. Age-independent refe-
rence values in a biomarker-selected 
healthy cohort were 3-28 ng/mL in men 
and 2-16 ng/mL in women (Dieplinger et 
al., 2009).In this study, ST2 level is 
analysed collaborating with the Prodia 
Laboratory. 
6. End Points 
Study end points included: ST2 reduction 
rates, proportion of patients free of 
congestion (no dyspnea, no orthopnea, no 
rales and no peripheral edema) on day 3. 
Also considered safety (creatinine changes 
from day 1 to day 3) plus changes in potas-
sium from day 1 to day 3). 
7. Statistical Analysis 
Data is presented in mean ± SD and 
analyzed using SPSS 22 for windows with a 
p<0.05 was considered statistically signi-
ficant. To determine the mean difference 
between spironolactone and control groups 
before and after treatment, independent 
samples t test was used when the data were 
normally distributed. Mann Whitney test 
was used when the data were not normally 
distributed. To determine the mean diffe-
rence between pre and post treatment in a 
group of paired, samples t test was used 
when the data were normally distributed. 
Wilcoxon test was used when the data were 
not normally distributed. If data binomial, 
statistical analysis was tested by Chi Square 
test. 
8. Research Ethics 
The Ethics Committee of Dr. Moewardi/ 
Medical Faculty of Sebelas Maret Univer-
sity in Surakarta provided ethical clearance 
approval for this study. All patients 
provided written informed consent to 
participate in the study. 
 
RESULTS 
1. Baseline Characteristics 
This study aims to determine the effect of 
early spironolactone therapy to the ST2 
level and clinical changes in patients with 
ADHF. Thirty eight consecutive patients 
were randomized into two groups: spirono-
lactone group (standard therapy plus spiro-
nolactone 100 mgper day for 3 day, n=19) 
and control group (standard therapy, n= 
19). 
Baseline characteristics of patients in 
each group is shown in Table 1. The average 
of age in spironolactone group (mean= 
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59.53; SD= 11.96) was higher than control 
group (mean= 52.58; SD= 16.01), but it was 
statistically not significant (p= 0.138). The 
study groups were well balance in most cli-
nical characteristics include gender, etio-
logy of heart failure: Coronary Atheroscle-
rotic Disease (CAD) or non-CAD, left ven-
tricular ejection fraction (LVEF), ureum, 
creatinine, potassium and ST2 levels as well 
as the treatment of heart failure (furose-
mide, ACEI/ARB, nitrate and digitalis). 
Digitalis treatment in some patients in the 
study group was related to atrial 
fibrillation. 






Mean ± SD/ n (%) Mean ± SD/ n(%) 















LVEF (%)  34.53 ±13.44 35.68 ±15.88 0.810 
Urea (mg/dL)  47.21 ±17.23 53.16 ±22.73 0.370 
Creatinin (mg/dL)  1.16 ±0.21 1.26 ±0.52 0.422 
Potassium (mg/dL)  3.95 ±0.63 4.05 ±0.60 0.618 
Natrium (mg/dL)  135.84 ± 4.92 134.0 ± 6.04 0.310 































2. The effect of early spironolactone 
therapy to the ST2 levels 
Prior therapy, the ST2 levels in spirono-
lactone group was higher (mean= 59.93; 
SD= 28.98 ng/mL) than control group 
(mean= 53.88; SD= 29.25 ng/mL), but it 
was statistically not significant (p= 0.526). 
After therapy (Table 2 and Table 3), the 
levels of ST2 at day-4 in spironolactone 
group (mean= 21.24; SD= 21. 29 ng/mL) 
was lower than control group (mean= 
34.15; SD= 21.20 ng/mL) and it was 
statistically significant (p= 0.034).  
In spironolactone group, the level of 
ST2 were decreased significantly from 
baseline (mean= 59.93; SD= 28.98 ng/mL 
prior therapy) to day-4 (mean= 21.24; SD= 
12.49 ng/mL) and it was statistically 
significant (p<0.001). 
In control group, the ST2 level also 
decreased significantly from baseline 
(mean= 53.88; SD= 29.25 ng/mL to day-4 
(mean= 34.15; SD= 21.20 ng/mL) with 
p<0.001.  
The reduction level of ST2 was statis-
tically significant between spironolactone 
group (mean= 36.96; SD= 21.29 ng/mL) 
and control group (mean= 19.73; SD= 16.48 
ng/mL) with p= 0.008. 
3. The effect of early spironolactone 
therapy to the clinical changes of 
ADHF 
Improvement of clinical symptoms of heart 
failure were observed based on anamnesis 
to the patient (no dispnea, no ortopnea). 
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The difference of clinical symptom changes 
were not statistically significant between 
two groups ( 63.2% in spironolactone group 
vs 31.6%, in control group, p= 0.051, RR 
2.0; 95% CI 0.95-4.22), but a greater pro-
portion of patients in the spironolactone 
group was free of congestion symptoms at 
day-3 (12 vs 6 patients) so it was clinically 
significant. Improvement of clinical signs of 
heart failure were observed based on phy-
sical examination to the patient (no rales, 
no pheripheral edema). The difference of 
clinical sign changes were not statistically 
significant between two groups (73.7% in 
spironolactone group vs 47.4%, in control 
group, p= 0.097, RR 1.56; 95% CI 0.90-
2.68), but a greater proportion of patients 
in the spironolactone group was free of 
congestion sign at day-3 (14 vs 9 patients) 
so it was clinically significant (Table 4).
Table 2. Mean Difference of the ST2 Levels in study groups 
Variable 
  

























































Table 3. ST2 level prior and after treatment between two groups 
Variable 
 














SE p 95% CI 
Lower-
Upper 












38.69 7.24 <0.001 
24.01-
53.38 

















Worsening renal function (increase in Cr 
≥0.3 mg/dL or eGFR decline >25% from 
baseline) was observed in control group (1 
patient), but none in spironolactone group 
(5.3% vs 0%, p= 0.311). Serum potassium 
(K+) levels did not differ significantly 
between groups and no patient developed 
hyperkalemia (serum K+ ≥5.5 mg/dL). 
Hypokalemia (serum K+ ≤3.5 mg/dL) was 
less frequent in spironolactone group 
(15.8% vs 47.4%) and statistically signifi-
cant (p=0.036, RR 0.33; 95% CI  0.1-1.0). It 
means that an additional early spirono-
lactone therapy in patients with ADHF will 
reduce the relative risk for hypokalemia by 
33% compared to the control group (see 
Table 5). 
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Table 4. Side Effects of ADHF treatments 
Variable Side Effects p Risk Estimation 
Yes No RR (95% CI) 
Hypokalemia 
Spironolactone group 
     
Number 





   
Control group 
Number 














































   
 
Table 5.Changes in clinical signs and symptom at day-3 
Variable Free of congestion at day-3 p Risk Estimation 
Yes No RR CI 95% 
Symptom of HF 
Spironolactone group 
Number 

































Sign of HF 
Spironolactone group 
Number 



































The management of Acute Decompensated 
Heart Failure (ADHF) iniatialy focuses on 
life threathening reversible precipitants, 
and therapeutic fluid removal to relieve 
congestion, optimize cardiac function and 
minimize end-organ damage (Gheorghiade 
et al., 2009).Importantly, aldosterone levels 
are elevated in ADHF despite therapy with 
ACEI/ARB and beta blockers, and Mineral-
ocorticoid receptor (MR) activation may 
contribute to both acute decompensation 
(i.e. fluid retention and vasoconstriction) 
and progressive cardiorenal dysfunction 
(i.e. fibrosis, inflammation, oxidative stress 
and hypertrophy) in patient with heart 
failure (HF) (Struthers et al., 2008). The 
use of Mineralocorticoid Receptor Anta-
gonist (MRA) in AHF may be a key thera-
peutic intervention in patiens with worsen-
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ing HF by virtue of their ability to augment 
diuresis and attenuate the pathological 
effects of MR activation (Struthers et al., 
2002; Albaghdadi et al., 2011). 
This study was a experimental, single 
blind randomized controlled trial that eva-
luate the effects of early administration of 
100 mg per day spironolactone to standard 
therapy on the clinical changes of HF and 
particularly their effect on levels of ST2 in 
patient with ADHF.ST2 is a biomarker for 
neurohormonal activation in HF patients 
and serve as indicators of cardiac muscle 
damage, treatment monitoring and prog-
nosis (Kakkar et al., 2008; Sabatine et al., 
2008). The results showed that after treat-
ment, the levels of ST2 at day-4 were 
decreased significantly from baseline in two 
groups, but the decreasing ST2 levelswere 
more pronounced in spironolactone group 
than control group. There was also a signi-
ficant different of delta ST2 between two 
groups (36.96 ± 21.29 ng/mL inspirono-
lactone group vs 19.73 ± 16.48 ng/mL in 
control group, p= 0.008). The effects of 
early spironolactone therapy on the ST2 
levels in ADHF patients have not been 
studied before. Research by Lax et al, that 
evaluate the effects of MRAs (eplerenone 
and spironolactone) in animal models of 
myocardial infarction and Left Ventricle 
(LV) disfunction by permanent ligation of 
anterior coronary artery in 45 male Wistar 
rats, showed that treatment with MRAs 
down regulated Galectin-3 (Gal-3) and 
Tranforming Growth Factor Beta (TGF-β), 
and enhanced Interleukin 33 (IL33/ST2) 
signaling with lower expression sST2. 
Modulation of Gal-3 and IL33/ST2 induced 
by MRA correlated withlower expression 
levels of fibrosis and inflammation marker 
(Collagen types I and III, IL-6,TNF-α and 
MCP1). There was no difference between 
eplerenone or spironolactone groups (Lax 
et al., 2015). 
The difference in changes of clinical 
signs and symptoms of ADHF were not 
statistically significant in the spironolac-
tone group and the control group, but the 
proportion of clinical signs and symptoms 
improvement was greater in patients with 
spironolactone group than the control 
group (clinically significant). The previous 
study by Ferreira et al., whoevaluated the 
effects of spironolactone in patients with 
ADHF by examining N Terminal-pro Natri-
uretuc Peptide (NT-proBNP) levels and 
clinical changes ofHF, adding spirono-
lactone 50-100 mg plus standard therapy, 
and concluded that early administration of 
spironolactone was safe, associated with 
earlier resolution of symptoms and signs of 
congestion as well as a more pronounced 
NT-proBNP reduction (Ferreira et al., 
2014). 
Providing diuresis while minimizing 
cardiorenal injury through exacerbation of 
neurohormonal and inflammatory path-
ways is important in AHF therapy. 
Agressive use of loop diuretics are the 
mainstay of early therapy in AHF, and are 
effective in reducing cardiac filling pres-
sures and alleviating symptomatic conges-
tion. However, loop diuretic induced natri-
uresis and diuresis are often associated 
with further neurohormonal activation 
electrolyte abnormalities and worsening 
renal function (Hasselblad et al., 2007; 
Domanski et al., 2003). Loop diuretic-
mediated increased in distal tubular 
sodium delivery lead to tubular hyper-
trophy and hyperplasia. Increased tubular 
sodium (Na+) also contributes to elevated 
renin–angiotensin–aldosteronesystem and 
sympathetic nervous system activity and 
ultimately elevated levels of aldosterone 
leading to up-regulated sodium channelsin 
the distal tubule. The structural and func-
tional alterations that result from elevated 
tubular sodium delivery contribute to 
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diureticresistance, in part, due to renal and 
neurohumoral responses to increased 
proximal Na+. Mineralocorticoid receptor 
antagonists act at thesedistal tubular sites 
and to augment natriuresis in the diuretic 
resistant and excess fluidin AHF patients 
(Domansk et al., 2011). 
The concern about excessive hyper-
kalemia prevent the prescription of MRAs 
in many clinical setting (Sanjay et al., 
2008). This study showed that early admi-
nistration of spironolactone are relatively 
safe, there was no evidence of hyperkalemia 
or worsening renal function in spirono-
lactone group, while in control group there 
was 1 incident of worsening kidney function 
without incidence of hyperkalemia. The 
concomitant use of i.v. diuretics with kali-
uretic properties could contributed to the 
absent of hyperkalemia. On the other hand, 
a significant difference of the incidence of 
hypokalemia was observed in spirono-
lactone group and control group (15.8% vs 
47.4%, p= 0.036), it showed that early 
spironolactone therapy can reduce the risk 
of hypokalemia up to 33% (RR= 0.33; 95% 
CI 0.1-1.0). Spironolactone is a potassium-
sparing diuretics, which can reduce the risk 
of hypokalemia due to the use of furo-
semide and potassium excretion as a result 
increased aldosterone levels (Ferreira et al., 
2014). 
Administration of spironolactone 100 
mg at the first 3 day plus standard therapy 
in patients with ADHF decreases levels of 
ST2, decreases risk of hypocalemic, and 
give greater proportion of clinical improve-
ment compared with standard therapy only. 
Early spironolactone therapy in ADHF may 
improve congestion through diuretic effect 
and prevention of neurohormonal activa-
tion, that showed with an early resolution 
of the congestive signs and simptoms and a 
more pronounced ST2 level reduction.  
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